-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 20, European time, the 2022 International Conference on Alzheimer's Disease and Parkinson's Disease (AD/PD) officially ended in Barcelona, Spain.
A six-day academic conference was held on research breakthroughs, drug development, early diagnosis, clinical trials, etc.
, which was held in the form of a combination of online and offline, attracting the participation of relevant experts and scholars in the field of neurology from all over the world
.
As the second most common neurodegenerative disease after Alzheimer's disease (AD), the pathogenesis of Parkinson's disease (PD) is still inconclusive.
Inflammation is associated with oxidative stress and mitochondrial dysfunction
.
In recent years, more and more studies have shown that the intestinal flora is highly correlated with the occurrence and development of Parkinson's disease
.
"Increasing data highlight the role of the gut microbiota in Parkinson's disease, and it is thought that the gut microbiota can modulate brain function in several ways
.
" Philip Scheltens, director of the Alzheimer's Center in Amsterdam, the Netherlands, said in a statement.
said at the meeting
.
Philip Scheltens gave an opening speech at the symposium.
At the symposium
on "Gut Microbiota and Parkinson's Disease: Significance for Pathogenesis and Disease Treatment" organized by Green Valley Medical Technology, three domestic and foreign experts shared their insights into Parkinson's disease.
Mechanistic insights, drug and non-drug therapies for Kinson's disease
.
Teus Van Laar, medical director of the Parkinson's Disease Specialized Center at the University of Groningen in the Netherlands, shared the relevant research on the association between intestinal flora and Parkinson's disease in the report "Personalized Medicine in Parkinson's Disease and the Role of the Brain-Gut Axis"
.
For example, the research results of the Sampson research team of the California Institute of Technology published in Cell in 2016, the team used Parkinson's disease model mice for research, and the brains of this mouse have α-synuclein specific to Parkinson's disease.
, also showing abnormal movement symptoms
.
When they cleared the gut bacteria from the mice, Parkinson's symptoms were relieved
.
When gut bacteria from Parkinson's patients were transplanted into already germ-free Parkinson's disease model mice, the mice again had abnormal movements, while if gut bacteria from healthy people were transplanted, they did not develop Parkinson's symptoms
.
This result suggests that gut microbes are closely involved in the pathogenesis of Parkinson's disease[1]
.
Teus Van Laar shared the report "Personalized medicine and the role of brain-gut axis in Parkinson's disease" Geng Meiyu
, academic director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences shared the report "Mechanistic Insights of GV-971 Against Parkinson's Disease in Animal Models", We explored whether GV-971 could combat Parkinson's disease, which has a similar pathogenesis to Alzheimer's disease, by targeting the brain-gut axis
.
GV-971 is the world's first drug targeting the brain-gut axis for the treatment of Alzheimer's disease.
It can reduce neuroinflammation in the brain by regulating the intestinal flora and reducing abnormal metabolites of the flora
.
The results of China's Phase III clinical study showed that GV-971 has the characteristics of fast onset, continuous and steady improvement in cognitive function of patients, and good safety, and the incidence of adverse events is comparable to the placebo group [2]
.
In 2021, The Lancet clearly stated that there are only two AD disease course-modifying drugs on the market, and GV-971 is one of them [3]
.
On this basis, the team of Green Valley Research Institute carried out preclinical research on the treatment of Parkinson's disease with GV-971 based on the common pathological mechanism of neurodegenerative diseases
.
"Non-clinical model studies have shown that GV-971 has a unique mechanism of action to reshape the gut microbiota balance in a variety of Parkinson's disease animal models by targeting the gut microbiota, while reducing α-synuclein in the gut Deposition in the tract and brain, and reduce neuroinflammation
.
" Geng Meiyu said, "GV-971 can help protect dopaminergic neurons and improve motor and non-motor symptoms
.
We also found that if the treatment time was longer, it could be observed Based
on
these findings, the U.
S.
Food and Drug Administration (FDA) has approved GV-971 on December 16, 2021 to conduct an international multicenter Phase II clinical trial for the treatment of Parkinson’s disease
.
This will be a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-controlled trial with a 36-week open-label extension, and plans to include 300 patients with early Parkinson's disease as clinical trial subjects in North America and Asia Pacific.
30 clinical centers were conducted to evaluate the efficacy and safety of the drug in the treatment of early Parkinson's disease
.
The international multi-center phase II clinical trial of GV-971 for the treatment of Parkinson's disease has been approved by the FDA.
Geng Meiyu said that the primary endpoint of this clinical trial will focus on the motor function of patients, and will also be based on non-motor symptom related scales.
assessments, in addition to exploratory endpoints, including biomarkers related to gut microbiota imbalances
.
In addition to targeting the brain-gut axis to reduce neuroinflammation, more and more studies have demonstrated that neuroinflammation is closely related to the occurrence and development of neurodegenerative diseases such as AD and PD
.
Chen Shengdi, a professor of neurology at Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, shared the report "Non-drug therapy for neurodegenerative diseases" at the symposium, introducing the help of cognitive and Tai Chi training for patients with cognitive impairment, and may help alleviate inflammation
.
Chen Shengdi's research team carried out two clinical projects to apply Tai Chi training to patients with early Parkinson's disease
.
The first study looked at improvements in motor and non-motor symptoms over a one-year period of training, including tai chi and brisk walking
.
The second study looked at the slowing effect of training on disease progression, with patients trained for an average of three years
.
During this period, compared with the Tai Chi group, more patients in the control group required increased use of 18 Parkinson's disease treatment drugs and had higher scores on the Unified Parkinson's Disease Rating Scale (UPDRS) version 3.
0, indicating that Tai Chi training can delay early stage The progression of Parkinson's disease
.
In addition, the team also found that compared with the control group, the inflammatory cytokines in the patients were significantly reduced after Tai Chi training
.
Chen Shengdi shared the report "Non-drug therapy for neurodegenerative diseases",
Chen Shengdi said: "These findings show that cognitive training can improve the cognitive ability of patients with mild cognitive impairment, and Tai Chi can enhance cognitive training in delaying mild cognitive impairment.
In terms of cognitive decline in patients with disabilities, Tai Chi training can improve motor symptoms and cognitive function in patients with Parkinson's disease, and may delay the progression of Parkinson's disease
.
The mechanisms of cognitive and Tai Chi training effects may be related to increasing neuroplasticity, reducing Inflammation, etc.
"
References:
A six-day academic conference was held on research breakthroughs, drug development, early diagnosis, clinical trials, etc.
, which was held in the form of a combination of online and offline, attracting the participation of relevant experts and scholars in the field of neurology from all over the world
.
As the second most common neurodegenerative disease after Alzheimer's disease (AD), the pathogenesis of Parkinson's disease (PD) is still inconclusive.
Inflammation is associated with oxidative stress and mitochondrial dysfunction
.
In recent years, more and more studies have shown that the intestinal flora is highly correlated with the occurrence and development of Parkinson's disease
.
"Increasing data highlight the role of the gut microbiota in Parkinson's disease, and it is thought that the gut microbiota can modulate brain function in several ways
.
" Philip Scheltens, director of the Alzheimer's Center in Amsterdam, the Netherlands, said in a statement.
said at the meeting
.
At the symposium
on "Gut Microbiota and Parkinson's Disease: Significance for Pathogenesis and Disease Treatment" organized by Green Valley Medical Technology, three domestic and foreign experts shared their insights into Parkinson's disease.
Mechanistic insights, drug and non-drug therapies for Kinson's disease
.
Teus Van Laar, medical director of the Parkinson's Disease Specialized Center at the University of Groningen in the Netherlands, shared the relevant research on the association between intestinal flora and Parkinson's disease in the report "Personalized Medicine in Parkinson's Disease and the Role of the Brain-Gut Axis"
.
For example, the research results of the Sampson research team of the California Institute of Technology published in Cell in 2016, the team used Parkinson's disease model mice for research, and the brains of this mouse have α-synuclein specific to Parkinson's disease.
, also showing abnormal movement symptoms
.
When they cleared the gut bacteria from the mice, Parkinson's symptoms were relieved
.
When gut bacteria from Parkinson's patients were transplanted into already germ-free Parkinson's disease model mice, the mice again had abnormal movements, while if gut bacteria from healthy people were transplanted, they did not develop Parkinson's symptoms
.
This result suggests that gut microbes are closely involved in the pathogenesis of Parkinson's disease[1]
.
, academic director of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences shared the report "Mechanistic Insights of GV-971 Against Parkinson's Disease in Animal Models", We explored whether GV-971 could combat Parkinson's disease, which has a similar pathogenesis to Alzheimer's disease, by targeting the brain-gut axis
.
GV-971 is the world's first drug targeting the brain-gut axis for the treatment of Alzheimer's disease.
It can reduce neuroinflammation in the brain by regulating the intestinal flora and reducing abnormal metabolites of the flora
.
The results of China's Phase III clinical study showed that GV-971 has the characteristics of fast onset, continuous and steady improvement in cognitive function of patients, and good safety, and the incidence of adverse events is comparable to the placebo group [2]
.
In 2021, The Lancet clearly stated that there are only two AD disease course-modifying drugs on the market, and GV-971 is one of them [3]
.
On this basis, the team of Green Valley Research Institute carried out preclinical research on the treatment of Parkinson's disease with GV-971 based on the common pathological mechanism of neurodegenerative diseases
.
"Non-clinical model studies have shown that GV-971 has a unique mechanism of action to reshape the gut microbiota balance in a variety of Parkinson's disease animal models by targeting the gut microbiota, while reducing α-synuclein in the gut Deposition in the tract and brain, and reduce neuroinflammation
.
" Geng Meiyu said, "GV-971 can help protect dopaminergic neurons and improve motor and non-motor symptoms
.
We also found that if the treatment time was longer, it could be observed Based
on
these findings, the U.
S.
Food and Drug Administration (FDA) has approved GV-971 on December 16, 2021 to conduct an international multicenter Phase II clinical trial for the treatment of Parkinson’s disease
.
This will be a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-controlled trial with a 36-week open-label extension, and plans to include 300 patients with early Parkinson's disease as clinical trial subjects in North America and Asia Pacific.
30 clinical centers were conducted to evaluate the efficacy and safety of the drug in the treatment of early Parkinson's disease
.
Geng Meiyu said that the primary endpoint of this clinical trial will focus on the motor function of patients, and will also be based on non-motor symptom related scales.
assessments, in addition to exploratory endpoints, including biomarkers related to gut microbiota imbalances
.
In addition to targeting the brain-gut axis to reduce neuroinflammation, more and more studies have demonstrated that neuroinflammation is closely related to the occurrence and development of neurodegenerative diseases such as AD and PD
.
Chen Shengdi, a professor of neurology at Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, shared the report "Non-drug therapy for neurodegenerative diseases" at the symposium, introducing the help of cognitive and Tai Chi training for patients with cognitive impairment, and may help alleviate inflammation
.
Chen Shengdi's research team carried out two clinical projects to apply Tai Chi training to patients with early Parkinson's disease
.
The first study looked at improvements in motor and non-motor symptoms over a one-year period of training, including tai chi and brisk walking
.
The second study looked at the slowing effect of training on disease progression, with patients trained for an average of three years
.
During this period, compared with the Tai Chi group, more patients in the control group required increased use of 18 Parkinson's disease treatment drugs and had higher scores on the Unified Parkinson's Disease Rating Scale (UPDRS) version 3.
0, indicating that Tai Chi training can delay early stage The progression of Parkinson's disease
.
In addition, the team also found that compared with the control group, the inflammatory cytokines in the patients were significantly reduced after Tai Chi training
.
Chen Shengdi said: "These findings show that cognitive training can improve the cognitive ability of patients with mild cognitive impairment, and Tai Chi can enhance cognitive training in delaying mild cognitive impairment.
In terms of cognitive decline in patients with disabilities, Tai Chi training can improve motor symptoms and cognitive function in patients with Parkinson's disease, and may delay the progression of Parkinson's disease
.
The mechanisms of cognitive and Tai Chi training effects may be related to increasing neuroplasticity, reducing Inflammation, etc.
"
References:
- Timothy R.
Sampson et al.
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
Cell, December 2016 DOI: 10.
1016/j.
cell.
2016.
11.
018 - Xiao, S.
, Chan, P.
, Wang, T.
, Hong, Z.
, Wang, S.
, Kuang, W.
, .
.
.
& Zhang, Z.
(2021).
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Alzheimer's research & therapy, 13(1), 1-11. - Philip Scheltens, Bart De Strooper, Miia Kivipelto, et al.
Alzheimer's disease.
The Lancet.
2021, April 24, 397(10284):1577-1590. - Biogen.
(2021).
HIGHLIGHTS OF PRESCRIBING INFORMATION.
retrieved November 27 2021 from : https:// Timothy R.
Sampson et al.
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
Cell, December 2016 DOI: 10.
1016/j.
cell.
2016.
11.
018 Timothy R. - Xiao, S.
, Chan, P.
, Wang, T.
, Hong, Z.
, Wang, S.
, Kuang, W.
, .
.
.
& Zhang, Z.
(2021).
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Alzheimer's research & therapy, 13(1), 1-11. Xiao, S. - Philip Scheltens, Bart De Strooper, Miia Kivipelto, et al.
Alzheimer's disease.
The Lancet.
2021, April 24, 397(10284):1577-1590. Philip Scheltens, Bart De Strooper, Miia Kivipelto, et al. - Biogen.
(2021).
HIGHLIGHTS OF PRESCRIBING INFORMATION.
retrieved November 27 2021 from : https:// OF PRESCRIBING INFORMATION.
retrieved November 27 2021 from : https:// CRISPR technology is used in cancer patients for the first time in the United States!
Sampson et al.
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
Cell, December 2016 DOI: 10.
1016/j.
cell.
2016.
11.
018
, Chan, P.
, Wang, T.
, Hong, Z.
, Wang, S.
, Kuang, W.
, .
.
.
& Zhang, Z.
(2021).
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Alzheimer's research & therapy, 13(1), 1-11.
Alzheimer's disease.
The Lancet.
2021, April 24, 397(10284):1577-1590.
